ALMKT — Mauna Kea Technologies SA Share News
0.000.00%
- €18.03m
- €27.51m
- €8.22m
Brief: Mauna Kea Technologies: Capital Increase Of About EUR 12.5 Million Reserved For Two Investors
Brief: Mauna Kea Technologies Receives U.S. FDA Clearance Of Its Next-Generation Cellvizio® Platform
Brief: Mauna Kea Technologies Q2 Sales up at 1.7 Million euros
Brief: Mauna Kea Technologies Completes Patient Enrollment In Pioneer Study
Brief: Mauna Kea Unveils Next-Generation Cellvizio Platform
Brief: Mauna Kea Technologies Signs With Hospital For IBS Food Allergy Application
Brief: Mauna Kea Technologies Q1 Sales Stable At 1.6 Million Euros
Brief: Mauna Kea Supports Research Use Of Cellvizio On COVID-19 Patients
Brief: Mauna Kea: Publication Of Peer-Reviewed Study On Cellvizio
Brief: Mauna Kea Technologies Q4 Sales At 2.4 Million Euros, Up 41%
Brief: Mauna Kea Technologies Q4 Sales Expected In Range Of 2.2 To 2.3 Million Euros
Brief: Mauna Kea Technologies Partners With Telix Pharmaceuticals Limited
Brief: Mauna Kea Technologies Announces New Publications On Cellvizio
Brief: Mauna Kea Technologies 9-Month Total Sales Down At 4.1 Million Euros
Brief: Mauna Kea Technologies H1 Net Loss Narrows To EUR 6.7 Million
Brief: Mauna Kea Technologies Q2 Total Sales Down At 0.6 Million Euros
Brief: Mauna Kea Technologies Gets State-Guaranteed Loan Of EUR 4 Million
Brief: Mauna Kea Technologies Draws Down Second Tranche Of Loan Agreement With EIB
Brief: Mauna Kea Technologies Launches Study For Diagnosis Of Peripheral Lung Nodules